Your browser doesn't support javascript.
loading
Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate.
Desai, Grishma; Ramachandran, Gurumurthy; Goldman, Emanuel; Esposito, William; Galione, Antony; Lal, Altaf; Choueiri, Toni K; Fay, Andre; Jordan, William; Schaffner, Donald W; Caravanos, Jack; Grignard, Etienne; Mainelis, Gediminas.
Afiliación
  • Desai G; Grignard Company, LLC, Rahway, New Jersey 07065, United States.
  • Ramachandran G; Department of Environmental Health and Engineering, Johns Hopkins Education and Research Center for Occupational Safety and Health, Bloomberg School of Public Health, Whiting School of Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, United States.
  • Goldman E; Department of Microbiology, Biochemistry, and Molecular Genetics, Rutgers-New Jersey Medical School, Newark, New Jersey 07103, United States.
  • Esposito W; Founder, Ambient Group, Inc., New York, New York 10018, United States.
  • Galione A; Department of Pharmacology, University of Oxford, Oxford OX1 3QT, United Kingdom.
  • Lal A; Former Chief, Molecular Vaccine Section, CDC. Former Health Attaché and HHS Regional Representative for South Asia, Former US FDA Country Director - India, Atlanta, Georgia 30345, United States.
  • Choueiri TK; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, United States.
  • Fay A; Pontifícia Universidade Católica do Rio Grande do Sul, School of Medicine, Porto Alegre, Rio Grande do Sul 90619-900, Brazil.
  • Jordan W; Former Deputy Director, Office of Pesticide Programs, Environmental Protection Agency, William Jordan Consulting, Washington, District of Columbia 20016, United States.
  • Schaffner DW; Department of Food Science, School of Environmental and Biological Sciences, Rutgers, The State University of NJ, New Brunswick, New Jersey 08902, United States.
  • Caravanos J; Clinical Professor of Environmental Public Health Services, New York University, New York, New York 10012, United States.
  • Grignard E; Founder, CEO, Grignard Pure, LLC, Rahway, New Jersey 07065, United States.
  • Mainelis G; Department of Environmental Sciences, School of Environmental and Biological Sciences, Rutgers, The State University of NJ, New Brunswick, New Jersey 08901, United States.
Environ Sci Technol ; 57(10): 4231-4240, 2023 03 14.
Article en En | MEDLINE | ID: mdl-36853925
ABSTRACT
Grignard Pure (GP) is a unique and proprietary blend of triethylene glycol (TEG) and inert ingredients designed for continuous antimicrobial treatment of air. TEG has been designated as a ″Safer Chemical" by the US EPA. GP has already received approval from the US EPA under its Section 18 Public Health Emergency Exemption program for use in seven states. This study characterizes the efficacy of GP for inactivating MS2 bacteriophage─a nonenveloped virus widely used as a surrogate for SARS-CoV-2. Experiments measured the decrease in airborne viable MS2 concentration in the presence of different concentrations of GP from 60 to 90 min, accounting for both natural die-off and settling of MS2. Experiments were conducted both by introducing GP aerosol into air containing MS2 and by introducing airborne MS2 into air containing GP aerosol. GP is consistently able to rapidly reduce viable MS2 bacteriophage concentration by 2-3 logs at GP concentrations of 0.04-0.5 mg/m3 (corresponding to TEG concentrations of 0.025 to 0.287 mg/m3). Related GP efficacy experiments by the US EPA, as well as GP (TEG) safety and toxicology, are also discussed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 / Antiinfecciosos Límite: Humans Idioma: En Revista: Environ Sci Technol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 / Antiinfecciosos Límite: Humans Idioma: En Revista: Environ Sci Technol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos